trial · primary record
imetelstat
High-risk Myeloid Malignancy
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 27 |
| Primary completion | 2031-02 |
| Primary endpoint | Maximum tolerated dose (MTD) of imetelstat |
| Registry ID | NCT07909733 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:25.661Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07909733
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.